Loading...
12/16 00:54
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with improved margins, positive EBITDA, and increased revenue. Despite some sector challenges, there is optimism in data monetization, operational efficiency, and potential partnerships. The Q&A highlights cautious optimism about market conditions and data licensing opportunities. The lack of debt and positive cash flow further support a positive outlook. Given these factors, the stock price is likely to experience a positive movement, although not strongly positive due to market uncertainties.
Total Revenue $17 million, an increase of 42% year-over-year from $12 million, driven by the successful closure of the inaugural data deal and growth in core services.
Research Service Revenue $12.5 million, an increase of 4% year-over-year from $12 million, reflecting stable demand in core services.
Data Revenue Contribution $4.5 million, a new revenue stream indicating early traction of the new platform.
Income from Operations $4.5 million, compared to a loss of $2.6 million in the prior year, attributed to improved operational efficiency and revenue growth.
Adjusted EBITDA $5.2 million, compared to an adjusted loss of $1.7 million in the prior year, reflecting strong revenue growth and cost management.
Total Cost of Sales $6.6 million, a decrease of 16% year-over-year from $7.8 million, primarily due to reduced salary expenses and lab costs.
Gross Margin 61%, improved due to high margin data revenue.
Research Service Margins 48%, an increase from 35% year-over-year, driven by operational efficiencies.
R&D Expense $1.7 million, a decrease of 21% year-over-year from $2.2 million, due to optimized spending.
G&A Expense $1.8 million, a decrease of $200,000 year-over-year, primarily due to reductions in salary expenses.
Total Revenue Year-to-Date $45 million, an increase of 22% year-over-year from $36 million.
Total Cost of Sales Year-to-Date $21 million, a decrease of 4% year-over-year from $21.9 million.
Total Gross Margin Year-to-Date 53%, improved from 40% year-over-year, driven by high margin data revenue and operational efficiencies.
Cash on Balance Sheet $3.2 million, with no debt, indicating a solid balance sheet.
Cash Generated by Operating Activities $900,000 for the quarter, reflecting improved operational results.
Cash Used in Investment Activities Approximately $500,000 for the quarter.
Net Quarterly Increase in Cash $400,000, primarily from improved operational results, offset by an increase in accounts receivable.
Record Revenue: Champions Oncology reported record revenue of $17 million for Q3 2025.
Data Revenue Contribution: Data revenue contribution was $4.5 million, indicating early traction of the new platform.
Expansion of Data Set: The company is actively expanding its collection of unique tumor models and enhancing their characterization.
Operational Efficiencies: The company has improved cost management and profitability through enhanced quality, increased efficiency, and scalability.
Gross Margin Improvement: Gross margin for the quarter was 61%, lifted by high-margin data revenue.
R&D Expense Reduction: R&D expense declined by 21% to $1.7 million as part of cost optimization.
First Data Deal: Champions Oncology successfully closed its inaugural data deal, licensing its deep multiomic data set.
Long-term Growth Strategy: The company aims to build the world’s most comprehensive biological data set from clinically relevant tumor populations.
Market Environment: The biopharmaceutical sector remains tight, leading to potential performance volatility despite a slight recovery in R&D budgets and capital raising.
Funding Challenges: The company is facing a challenging funding environment, which may impact its ability to raise capital for its drug development subsidiary, Corellia.
Revenue Projections: It is premature to forecast the number of deals, their average size, or the frequency of data revenue contributions to overall results.
Operational Volatility: Short-term volatility in research service revenue is anticipated, which may affect financial performance.
Cost Management: While operating expenses have decreased, fluctuations in research service margins are expected over the next two quarters.
Record Revenue: Q3 marked a transformative quarter for Champions Oncology, underscored by our record revenue of $17 million and the successful closure of our inaugural data deal.
Core Services Business: Our core services business remains at the forefront, driven by our industry leading PDX bank and its precisely characterized multiomic data.
Data Deal: The recently closed data deal exemplifies our strategic vision where we licensed our existing deep multiomic data set while also acquiring prospective omic data sets.
Long-term Growth: Despite challenges, we believe we are on a path towards long term growth.
Expansion of Data Set: We are actively exploring ways to extract greater value from our data and expanding our collection of unique tumor models.
Revenue Growth Guidance: We have reaffirmed our full year revenue growth guidance of 10% to 15%.
Long-term Margin Expansion: We anticipate long term margin expansion exceeding 15% as long term revenue growth.
Cash Position: Our balance sheet is solid and our cash position is poised to increase in the coming quarters.
Short-term Volatility: While we anticipate short term volatility in research service revenue, we remain confident in our long term growth trajectory.
Shareholder Return Plan: We have reaffirmed our full year revenue growth guidance of 10% to 15% and continue to focus on expanding our data business, enhancing profitability and driving shareholder value.
Cash Position: We ended the quarter with $3.2 million of cash on the balance sheet and no debt.
Cash Generated: For the quarter, cash generated by operating activities was $900,000.
Cash Used in Investment Activities: Cash used in investment activities was approximately $500,000.
Quarterly Cash Increase: The net $400,000 quarterly increase in cash was primarily from an improvement in operational results.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
